Suppr超能文献

相似文献

1
Octa-functional PLGA nanoparticles for targeted and efficient siRNA delivery to tumors.
Biomaterials. 2012 Jan;33(2):583-91. doi: 10.1016/j.biomaterials.2011.09.061. Epub 2011 Oct 19.
2
PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells.
Int J Nanomedicine. 2012;7:4269-83. doi: 10.2147/IJN.S33666. Epub 2012 Aug 3.
8
SiRNA drug delivery by biodegradable polymeric nanoparticles.
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2821-8. doi: 10.1166/jnn.2006.436.
9
Multi-layered nanoparticles for combination gene and drug delivery to tumors.
Biomaterials. 2014 Nov;35(34):9343-54. doi: 10.1016/j.biomaterials.2014.07.043. Epub 2014 Aug 8.

引用本文的文献

1
Functionalized chitosan as nano-delivery platform for CRISPR-Cas9 in cancer treatment.
Asian J Pharm Sci. 2025 Jun;20(3):101041. doi: 10.1016/j.ajps.2025.101041. Epub 2025 Feb 26.
2
Nanotechnology approaches to drug delivery for the treatment of ischemic stroke.
Bioact Mater. 2024 Sep 23;43:145-161. doi: 10.1016/j.bioactmat.2024.09.016. eCollection 2025 Jan.
3
The landscape of nanoparticle-based siRNA delivery and therapeutic development.
Mol Ther. 2024 Feb 7;32(2):284-312. doi: 10.1016/j.ymthe.2024.01.005. Epub 2024 Jan 10.
4
Engineering siRNA therapeutics: challenges and strategies.
J Nanobiotechnology. 2023 Oct 18;21(1):381. doi: 10.1186/s12951-023-02147-z.
5
Megakaryocyte membrane-wrapped nanoparticles for targeted cargo delivery to hematopoietic stem and progenitor cells.
Bioeng Transl Med. 2022 Nov 29;8(3):e10456. doi: 10.1002/btm2.10456. eCollection 2023 May.
6
Application of nanotechnology in reversing therapeutic resistance and controlling metastasis of colorectal cancer.
World J Gastroenterol. 2023 Apr 7;29(13):1911-1941. doi: 10.3748/wjg.v29.i13.1911.
8
Single small molecule-assembled nanoparticles mediate efficient oral drug delivery.
Nano Res. 2019 Oct;12(10):2468-2476. doi: 10.1007/s12274-019-2470-0. Epub 2019 Jul 24.
9
Silencing VDAC1 to Treat Mesothelioma Cancer: Tumor Reprograming and Altering Tumor Hallmarks.
Biomolecules. 2022 Jun 27;12(7):895. doi: 10.3390/biom12070895.
10
ZNF117 regulates glioblastoma stem cell differentiation towards oligodendroglial lineage.
Nat Commun. 2022 Apr 22;13(1):2196. doi: 10.1038/s41467-022-29884-3.

本文引用的文献

1
Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides.
Biomaterials. 2011 Sep;32(26):6194-203. doi: 10.1016/j.biomaterials.2011.04.053. Epub 2011 Jun 12.
2
Targeted nanoparticles deliver siRNA to melanoma.
J Invest Dermatol. 2010 Dec;130(12):2790-8. doi: 10.1038/jid.2010.222. Epub 2010 Aug 5.
3
A status report on RNAi therapeutics.
Silence. 2010 Jul 8;1(1):14. doi: 10.1186/1758-907X-1-14.
4
Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs.
Science. 2010 May 21;328(5981):1031-5. doi: 10.1126/science.1183057. Epub 2010 Apr 8.
5
Intravenous hemostat: nanotechnology to halt bleeding.
Sci Transl Med. 2009 Dec 16;1(11):11ra22. doi: 10.1126/scitranslmed.3000397.
6
Stealth nanoparticles: high density but sheddable PEG is a key for tumor targeting.
J Control Release. 2010 Aug 3;145(3):178-81. doi: 10.1016/j.jconrel.2010.03.016. Epub 2010 Mar 23.
7
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
Nature. 2010 Apr 15;464(7291):1067-70. doi: 10.1038/nature08956. Epub 2010 Mar 21.
8
Tissue-penetrating delivery of compounds and nanoparticles into tumors.
Cancer Cell. 2009 Dec 8;16(6):510-20. doi: 10.1016/j.ccr.2009.10.013.
9
Ligand-modified gene carriers increased uptake in target cells but reduced DNA release and transfection efficiency.
Nanomedicine. 2010 Apr;6(2):334-43. doi: 10.1016/j.nano.2009.09.001. Epub 2009 Oct 2.
10
Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice.
J Clin Invest. 2009 Mar;119(3):661-73. doi: 10.1172/JCI37515. Epub 2009 Feb 23.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验